h.pylori control: antibiotics and vaccine development
|
h.pylori vaccine developmentAn effective vaccine against H. pylori therefore remains a preferential option, especially for low income population who would particularly benefit given the high prevalence of disease associated with this infection in these countries and the likely lower costs of a vaccine approach as compared to other strategies. Importantly, while there are few definitive studies, a vaccine against H. pylori that reduces the incidence of gastric cancer will likely be cost-effective in both developed countries and in low income countries.
The development of a vaccine to prevent or eradicate H. pylori infection has proven extremely challenging. Vaccinating with a surprisingly wide range of antigens, adjuvants and delivery systems can produce a modest reduction in H. pylori colonization levels in mice, However attempts to translate this partial success in animal models to clinical trial have proven unsuccessful. The majority of early H. pylori vaccine clinical trials focused on the urease antigen with different adjuvants, routes and delivery systems generally proving ineffective in humans. |
our strategy: immunotherapy with milk
New therapeutic strategies are needed to solve the problems mentioned above. The approach of passive immunization with orally administered antibodies against H. pylori is likely to constitute one of the new therapeutic strategies. This approach mimics naïve protection in humans and has been shown to be effective in the prevention and treatment of a variety of pathogens, such as Rotavirus, Clostridium difficile, and Campylobacter jejuni. Many animal studies have shown that bovine antibody- containing milk against H. pylori reduces bacterial load, thus preventing and even eradicating H. pylori infection. The use of anti-H. pylori bovine antibodies in milk to control the H.pylori infection has many advantages such as low costs, nutrients, and good compliance, without the development of antibiotic resistance in H. pylori or other ora and the tolerance of long-term use. |
current progress
Phase 1 results are promising, showed 42.86% H.Pylori clearance rate. Phase 2 study have enrolled more than 200 patients.